| Drug Name |
Trientine |
| Drug ID |
BADD_D02279 |
| Description |
Triethylenetatramine (TETA) is a highly selective divalent Cu(II) chelator and orphan drug that revereses copper overload in tissues. Its salt form, trientine (triethylenetetramine dihydrochloride or 2,2,2-tetramine) was introduced in 1969 as an alternative to D-penicillamine. It consists of a polyamine-like structure different from D-penicillamine, as it lack sulfhydryl groups. It was previously approved by FDA in 1985 as second-line pharmacotherapy for Wilson's disease. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy, even with patients with decompensated liver disease at the outset, and prolonged TETA treatment is not associated with adverse effects as expected in penicillamine treatment. Its clinical applications on cancer, diabetes mellitus, Alzheimer's disease and vascular demetia are being studied. |
| Indications and Usage |
Trientine is a copper chelator used in the treatment of Wilson's disease as an alternative to D-penicillamine. It tends to be used in patients who are experiencing serious adverse effects from penicillamine therapy or intolerance of penicillamine. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AX12 |
| DrugBank ID |
DB06824
|
| KEGG ID |
D00736
|
| MeSH ID |
D014266
|
| PubChem ID |
5565
|
| TTD Drug ID |
D09VAZ
|
| NDC Product Code |
69238-1545 |
| UNII |
SJ76Y07H5F
|
| Synonyms |
Trientine | Triethylenetetramine | Trien | Syprine | Trientine Hydrochloride | Trientine Dihydrochloride |
